Amgen (AMGN) presents positive top-line results from the Phase 3 MINT trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Amgen Inc (NASDAQ: AMGN) | Delayed: 447.02 +8.68 (1.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $438.34 | 52 Week High | $176.85 | |||
| Open | $441.55 | 52 Week Low | $133.64 | |||
| Day High | $447.10 | P/E | 67.32 | |||
| Day Low | $437.19 | EPS | $6.64 | |||
| Volume | 391,840 | |||||
